Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix, a leader in regenerative medical devices, is set to announce its interim results for the first half of the year on September 10, 2024. Accompanying the results, a live presentation by top executives will be available for investors through the Investor Meet Company platform. The company specializes in patented decellularisation technology to create tissue scaffolds for a range of clinical applications.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
